

AKUMS

DRUGS & PHARMACEUTICALS LTD.



Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I,
(Adjoining CBSE Office) Delhi - 110083 (INDIA).

+91-11-69041000

CIN: L24239DL2004PLC125888

www.akums.in

akumsho@akums.net

+91-11-27023256

Ref: Akums/Exchange/2025-26/42

August 22, 2025

To,
The Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

To,
The Listing Department
BSE Limited
Rotunda Building, Phiroze Jeejeebhoy
Towers, Dalal Street, Fort, Mumbai -
400 001

Symbol: AKUMS

Scrip Code: 544222

Sub: Execution of Framework Agreement with Government of the Republic of Zambia

Respected Sir/Madam,

In continuation to the disclosure dated October 18th, 2024 and pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015, (SEBI Regulation) we would like to inform you that Akums Drugs and Pharmaceuticals Limited (hereinafter referred to as "Akums") has executed a Framework Agreement on 22nd August, 2025 with Government of the Republic of Zambia ("hereinafter referred to as "GRZ") to establish a local manufacturing facility in Zambia and to undertake the manufacturing and supply of Medicines in Zambia, with the objective of supporting GRZ national health programs and enhancing local production capabilities in Zambia. The facility, in the future, also plans to export to neighboring countries including, but not limited to, Zimbabwe, Namibia, Botswana, Malawi, Tanzania, Mozambique etc.

This Project shall be implemented through incorporation of a new joint venture company in Zambia in which Akums will be a majority partner owning 51% stake and a nominated Zambian state instrumentality owning 49% stake.

The facility is expected to commence manufacturing in 2028. The facility plans to manufacture general oral solids, liquids, injectables as well as beta-lactam products. Both the JV partners will jointly invest in the facility and commercial operations in ratio of their respective shareholding. Further, until such time as the Manufacturing Facility will be

Registered Office

304, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA).

+91-11-47511000

+91-11-27023256

established and becomes operational, the GRZ, through its state instrumentality, shall purchase Medicines from the Joint Venture Company having a minimum aggregate value of USD 50,000,000 (USD Fifty Million) over 2 years in 2026 and 2027, i.e. USD 25 million annually, which will be manufactured and supplied from Akums and/or its subsidiaries' facilities in India. The JV is expected to be established before the year end 2025.

Other details required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 are provided herein **Annexure-I**.

Annexure-I

Sr. No.	Particulars	Details of Framework Agreement
1	Name of the entity with whom agreement is signed	Akums Drugs and Pharmaceuticals Limited & Government of The Republic of Zambia
2	Area of agreement	Akums a leading contract development and manufacturing company in India, engaged in the development and manufacture of pharmaceutical products across a wide range of therapeutic areas, and is recognized for its contribution to pharmaceutical innovation and excellence. GRZ has identified the need to establish a local manufacturing base to ensure substantial access to essential medicines and medical supplies, promote economic growth and contribute to the improvement of the healthcare infrastructure in the Republic of Zambia. GRZ entered into a Framework Agreement with Akums to facilitate the collaboration for the establishment of a manufacturing facility in Zambia for essential pharmaceutical products. Pursuant to the Framework Agreement, the GRZ has nominated Zambian Partner to act as its implementing partner for the formation and operation of a joint venture with the Akums.
3	Domestic/International	International (Zambia)
4	Share exchange ratio	Not Applicable
5	Scope of business operation of agreement	Manufacturing, marketing, distribution, and sale of pharmaceutical products and medical supplies in Republic of Zambia, including to undertake the manufacturing and supplying of Medicines in the other African countries.
6	Details of consideration paid / received in agreement	Not Applicable

Registered Office

AKUMS DRUGS & PHARMACEUTICALS LTD.



Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I,
(Adjoining CBSE Office) Delhi - 110083 (INDIA).

www.akums.in

akumsho@akums.net

+91-11-69041000

CIN: L24239DL2004PLC125888

+91-11-27023256

7	Significant Terms and Conditions of agreement	<p>a) Akums will hold 51% stake in JV Company, along with certain Affirmative Voting Matters.</p> <p>b) Govt. of Zambia, either directly or through its Agency shall place Purchase Order of value of not less than USD 25 million (USD Twenty-Five Million) per annum from Akums.</p> <p>c) In furtherance of this collaboration, Akums has agreed to provide its proprietary technology, know-how, and technical expertise to the JV, and the Parties intend to enter into a separate Technology Transfer Agreement</p>
8	Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	No
9	Size of the entity	The size of the entity shall commensurate with the revenue of the Joint Venture formed.
10	Rationale and benefit expected.	Expansion of business in the African Countries and to capture the sizeable business opportunity.

This is to inform that the Supply Agreement, Joint Venture Agreement and Technology Transfer Agreement which are ancillary and incidental to the Framework Agreement executed on 22.08.2025, will be signed in due course of time preferably by end of September 2025.

This is for your kind information and record.

Thanking You

For Akums Drugs and Pharmaceuticals Limited

Dharamvir Malik
Company Secretary & Compliance Officer

Registered Office

304, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA).

+91-11-47511000

+91-11-27023256